513 related articles for article (PubMed ID: 12701830)
1. The curious characteristics of pyrazinamide: a review.
Zhang Y; Mitchison D
Int J Tuberc Lung Dis; 2003 Jan; 7(1):6-21. PubMed ID: 12701830
[TBL] [Abstract][Full Text] [Related]
2. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
[TBL] [Abstract][Full Text] [Related]
3. Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria.
Stehr M; Elamin AA; Singh M
Expert Rev Anti Infect Ther; 2015 May; 13(5):593-603. PubMed ID: 25746054
[TBL] [Abstract][Full Text] [Related]
4. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide.
Sun Z; Zhang Y
Antimicrob Agents Chemother; 1999 Mar; 43(3):537-42. PubMed ID: 10049264
[TBL] [Abstract][Full Text] [Related]
5. Genetic and phenotypic characterization of pyrazinamide-resistant mycobacterium tuberculosis complex isolates in Japan.
Miyagi C; Yamane N; Yogesh B; Ano H; Takashima T
Diagn Microbiol Infect Dis; 2004 Feb; 48(2):111-6. PubMed ID: 14972380
[TBL] [Abstract][Full Text] [Related]
6. pncA gene expression and prediction factors on pyrazinamide resistance in Mycobacterium tuberculosis.
Sheen P; Lozano K; Gilman RH; Valencia HJ; Loli S; Fuentes P; Grandjean L; Zimic M
Tuberculosis (Edinb); 2013 Sep; 93(5):515-22. PubMed ID: 23867321
[TBL] [Abstract][Full Text] [Related]
7. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Turkey.
Yüksel P; Tansel O
New Microbiol; 2009 Apr; 32(2):153-8. PubMed ID: 19579692
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa.
Bishop KS; Blumberg L; Trollip AP; Smith AN; Roux L; York DF; Kiepiela P
Int J Tuberc Lung Dis; 2001 Oct; 5(10):952-7. PubMed ID: 11605890
[TBL] [Abstract][Full Text] [Related]
9. Estimation of pyrazinamidase activity using a cell-free
Rueda D; Bernard C; Gandy L; Capton E; Boudjelloul R; Brossier F; Veziris N; Zimic M; Sougakoff W
Int J Mycobacteriol; 2018; 7(1):16-25. PubMed ID: 29516881
[TBL] [Abstract][Full Text] [Related]
10. [Characteristics of pncA gene in multidrug-resistant Mycobacterium tuberculosis isolates and its correlation with drug resistance to pyrazinamide].
Hong CY; Wang F; Gui J; Liu XL
Zhonghua Yu Fang Yi Xue Za Zhi; 2012 May; 46(5):436-9. PubMed ID: 22883731
[TBL] [Abstract][Full Text] [Related]
11. Metallochaperones Are Needed for Mycobacterium tuberculosis and Escherichia coli Nicotinamidase-Pyrazinamidase Activity.
Sheen P; Monsalve A; Campos J; Huerta R; Antiparra R; Arteaga H; Duran P; Bueno C; Kirwan DE; Gilman RH; Zimic M
J Bacteriol; 2020 Jan; 202(2):. PubMed ID: 31636108
[No Abstract] [Full Text] [Related]
12. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity.
Raynaud C; Lanéelle MA; Senaratne RH; Draper P; Lanéelle G; Daffé M
Microbiology (Reading); 1999 Jun; 145 ( Pt 6)():1359-1367. PubMed ID: 10411262
[TBL] [Abstract][Full Text] [Related]
13. Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene.
Bhuju S; Fonseca Lde S; Marsico AG; de Oliveira Vieira GB; Sobral LF; Stehr M; Singh M; Saad MH
Infect Genet Evol; 2013 Oct; 19():1-6. PubMed ID: 23770140
[TBL] [Abstract][Full Text] [Related]
14. Identification of Novel Efflux Proteins Rv0191, Rv3756c, Rv3008, and Rv1667c Involved in Pyrazinamide Resistance in Mycobacterium tuberculosis.
Zhang Y; Zhang J; Cui P; Zhang Y; Zhang W
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584158
[TBL] [Abstract][Full Text] [Related]
15. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil.
Barco P; Cardoso RF; Hirata RD; Leite CQ; Pandolfi JR; Sato DN; Shikama ML; de Melo FF; Mamizuka EM; Campanerut PA; Hirata MH
J Antimicrob Chemother; 2006 Nov; 58(5):930-5. PubMed ID: 16971417
[TBL] [Abstract][Full Text] [Related]
16. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
[TBL] [Abstract][Full Text] [Related]
17. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.
Hu Y; Coates AR; Mitchison DA
Int J Tuberc Lung Dis; 2006 Mar; 10(3):317-22. PubMed ID: 16562713
[TBL] [Abstract][Full Text] [Related]
18. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide.
Zhang Y; Scorpio A; Nikaido H; Sun Z
J Bacteriol; 1999 Apr; 181(7):2044-9. PubMed ID: 10094680
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance mechanism of PncA in Mycobacterium tuberculosis.
Rajendran V; Sethumadhavan R
J Biomol Struct Dyn; 2014; 32(2):209-21. PubMed ID: 23383724
[TBL] [Abstract][Full Text] [Related]
20. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.
Simões MF; Valente E; Gómez MJ; Anes E; Constantino L
Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
